CD4 and neoplasm: The model variable for activated T cells (ATC) was found to be highly sensitive throughout the treatment period (days 22, 112, 147) for Patient 1–5, to parameter c4 (maximum CD4+ T cell production rate stimulated by the interactions with tumor cells).